{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:42:27Z","timestamp":1789562547504,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,12]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Blinatumomab improved survival outcomes in B\u2010cell acute lymphoblastic leukemia (B\u2010ALL) patients with measurable residual disease (MRD) <10\u22124<\/jats:sup>. However, data on blinatumomab clearing MRD with high sensitivity of 10\u22126<\/jats:sup> remain scarce. This study evaluates the effectiveness of blinatumomab in eradicating extremely low level (up to <10\u22126<\/jats:sup>) of MRD, as detected by next\u2010generation sequencing (NGS), in children with B\u2010ALL.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients (n<\/jats:italic>\u2009=\u200919) whose MRD was undetectable by multiparameter flow cytometry (MFC) (sensitivity of 10\u22124<\/jats:sup>) but detectable by NGS after chemotherapy and followed by blinatumomab consolidation were included retrospectively.<\/jats:p><\/jats:sec>Results<\/jats:title>After one course of blinatumomab, 13\/19 patients (68%) successfully achieved NGS\u2010MRD clearance (undetectable). With a median follow\u2010up of 13.3\u2009months, three of patients who were NGS\u2010MRD positive relapsed within 1.8\u2009months, while another three remained complete remission.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Our study was the first to demonstrate that blinatumomab could further eradicate MRD after patients achieve MFC\u2010MRD undetectable in B\u2010ALL patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6771","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:40:49Z","timestamp":1702050049000},"page":"21978-21984","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B\u2010cell acute lymphoblastic leukemia patients detected by next\u2010generation sequencing"],"prefix":"10.1002","volume":"12","author":[{"given":"Min'er","family":"Gu","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-7140","authenticated-orcid":false,"given":"Yahong","family":"Xia","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2535","authenticated-orcid":false,"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Children's Hospital of Zhejiang University School of Medicine, The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0195-4"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29715"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25338"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655159"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615757"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43171-9"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171751"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157442"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007378"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28020131"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00300-2"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T08:54:10Z","timestamp":1705222450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":13,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cam4.6771"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6771","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}